We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay
Product News

Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay

Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay
Product News

Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Renishaw Diagnostics has announced the launch of the CE-IVD certified RenDx Multiplex Assay System together with its first assay, Fungiplex, a multiplex PCR in vitro test for the qualitative detection of Candida and Aspergillus DNA extracted from blood samples.

The assay is designed for use on the RenDx Multiplex Assay System, an automation and detection platform that allows processing of up to 45 samples in a single run and identifies 12 Candida and Aspergillus species using a unique detection technology known as surface enhanced resonance Raman spectroscopy (SERRS).

Rupert Jones, General Manager of Renishaw Diagnostics, said, “The CE-IVD launch of our RenDx platform and first assay marks a significant milestone, not just in the progress made here at Renishaw Diagnostics but more importantly, for infectious disease diagnostics throughout Europe. The extensive target menu for the Fungiplex assay, together with the high sensitivity that can be achieved through our exceptional detection technology, has the potential to aid earlier diagnosis, reduce overall spend and improve patient outcomes for those susceptible to these life threatening infections. We are looking forward to working with clinicians and laboratories to bring this assay into routine clinical use.”

Advertisement